Literature DB >> 31931473

Isolation of muscle stem cells from rat skeletal muscles.

Francesca Boscolo Sesillo1, Michelle Wong1, Amy Cortez2, Marianna Alperin3.   

Abstract

Muscle stem cells (MuSCs) are involved in homeostatic maintenance of skeletal muscle and play a central role in muscle regeneration in response to injury. Thus, understanding MuSC autonomous properties is of fundamental importance for studies of muscle degenerative diseases and muscle plasticity. Rat, as an animal model, has been widely used in the skeletal muscle field, however rat MuSC isolation through fluorescence-activated cell sorting has never been described. This work validates a protocol for effective MuSC isolation from rat skeletal muscles. Tibialis anterior was harvested from female rats and digested for isolation of MuSCs. Three protocols, employing different cell surface markers (CD106, CD56, and CD29), were compared for their ability to isolate a highly enriched MuSC population. Cells isolated using only CD106 as a positive marker showed high expression of Pax7, ability to progress through myogenic lineage while in culture, and complete differentiation in serum-deprived conditions. The protocol was further validated in gastrocnemius, diaphragm, and the individual components of the pelvic floor muscle complex (coccygeus, iliocaudalis, and pubocaudalis), proving to be reproducible. CD106 is an efficient marker for reliable isolation of MuSCs from a variety of rat skeletal muscles.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  CD106; Flow cytometry; Muscle stem cells; Pelvic floor muscles; Rat

Mesh:

Year:  2019        PMID: 31931473      PMCID: PMC7357689          DOI: 10.1016/j.scr.2019.101684

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


Introduction

Muscle stem cells (MuSCs), which reside between the sarcolemma and basal lamina, are required for the maintenance of adult muscle and muscle regeneration after injury (Mauro, 1961; Cheung and Rando, 2013). MuSCs exist in a tightly regulated quiescent state (Cheung and Rando, 2013). MuSC activation and proliferation is induced in response to increased mechanical load or to muscle injury (Relaix and Zammit, 2012; Tatsumi et al., 2001). Upon activation, MuSCs progress through the myogenic lineage until fusion with damaged myofibers occurs and muscle repair is achieved (Relaix and Zammit, 2012). The activation and differentiation of MuSCs has been extensively studied leading to the identification of sequentially expressed markers specific to each step of this process. Pax7, a transcription factor expressed by quiescent and early-activated MuSCs, is required for their functionality in homeostatic and regenerating conditions. Indeed, lack of Pax7 expression in MuSCs in vivo results in the absence of muscle regeneration following injury (Lepper et al., 2011; Seale et al., 2000). Upon activation, expression of MyoD, a transcription factor responsible for early commitment, promotes MuSC entry into the cell cycle (Cornelison and Wold, 1997). Finally, myogenin is activated, inducing terminal differentiation of MuSCs that can fuse together to form new myofibers or fuse with the existing myofibers. Studies of MuSCs autonomous properties rely mainly on the use of fluorescence-activated cell sorting (FACS). Isolation of MuSCs has been described in mouse, human, pig, and cow (Liu et al., 2015; Alexander et al., 2016; Uezumi et al., 2016; Ding et al., 2017; Ding et al., 2018; Maesner et al., 2016). A wide array of cell surface proteins have been reported as positive markers for MuSC identification and isolation, namely β1-integrin (CD29), CXCR4 (CD184), VCAM-1 (CD106), NCAM (CD56), α-7 integrin, CD34, tetraspanin (CD82), and CD318. Negative selection markers are conserved among laboratories and different mammalian species and include CD45 (lymphocytes), CD31 (endothelial cells), CD11b (macrophages), and Sca1 (fibro-adi-pogenic progenitors). Despite the extensive knowledge of MuSC identification markers and the broad spectrum of protocols employed for their isolation among multiple species, purification of MuSCs from rat has never been reported. The rat model has been extensively used in skeletal muscle research (Homberg et al., 2017). Rat, compared to other rodents, better recapitulates human muscle in architecture, physiology, and anatomy, making it a better model to study skeletal muscles. Muscle architecture (macroscopic arrangement of muscle fibers), which is fundamental for in vivo muscle function, has been shown to be similar between rats and humans, when compared to other animal models (Lieber and Friden, 2000). Comparative studies of abdominal muscles revealed a high degree of similarity within the same muscle groups between rat and human. The major architectural parameters (physiological cross sectional area, operational sarcomere length, and fiber orientation) were comparable, despite differences in body size and muscle mass (Brown et al., 2010). Additionally, studies of the female pelvic floor muscles showed that rats, compared to other commonly used laboratory animals, such as rabbit and mouse, were the closest to humans in terms of muscle design (Alperin et al., 2014). Moreover, the architectural difference index of rat pelvic floor muscles, which quantifies how closely rat muscle architecture resembles human muscle architecture, was comparable to that of non-human primates (Brown et al., 2010; Stewart et al., 2017). Furthermore, rat and human in vivo response to exercise shows similar qualitative and quantitative changes in plasma volume and blood biochemical parameters (Goutianos et al., 2015). Additionally, the rat physiology is closer to human physiology than mouse is, making rat a widely employed preclinical model for toxicology and safety studies (Noto et al., 2018). Indeed, like in human, the rat genome contains genes involved in protein breakdown and detection and detoxification of chemicals that have been lost in the mouse genome (Gibbs et al., 2004). Finally, rats are 10-fold larger than mice, which facilitates a wider variety of experimental procedures, collection of larger samples, and study of rare cell populations or low abundance molecules. The larger size of the rat also enables multiple concomitant measurements in a single animal, thus, reducing the number of animals needed. Given that the rat model is widely used in studies focused on skeletal muscles (Dwinell et al., 2011), we aimed to develop and validate an efficient and reliable protocol for MuSC isolation from the rat. The central role of MuSCs in the maintenance of muscle homeostasis and regeneration makes isolation and study of MuSC autonomous properties of fundamental importance. Here, we describe for the first time a method for isolation of rat MuSCs via FACS that relies on a single positive marker (VCAM-1 (CD106)) for identification of this cell population.

Materials and methods

Animals

Female 3-months old Sprague-Dawley rats (Envigo) were euthanized via CO2 inhalation followed by thoracotomy. Hind limb muscles (tibialis anterior (TA), gastrocnemius (GAS) and quadriceps), diaphragm (DIA), and pelvic floor muscles (coccygeus (C), iliocaudalis (ICa), and pubocaudalis (PCa)) were harvested. The University of California San Diego Institutional Animal Care and Use Committee approved all study procedures.

Cell isolation

Muscle stem cells (MuSCs) were isolated as described in Gromova et al., 2015 with minor modifications (Gromova et al., 2015). Cell isolation was performed using Ham’s F-10 supplemented with 10% horse serum. TA, GAS, DIA, C, ICa, and PCa were individually minced and incubated in 700 units/ml collagenase type II solution for 1.5 h and collagenase and dispase II solution (100 units/mL and 2 units/mL, respectively) for 30 min. Tissue was then passed through a 20 G needle and a 70 µm nylon filter. Antibody incubation was performed in 1 mL volume for 1 h. The positive markers used to identify the MuSCs were CD29, CD56, and CD106. The negative selection markers used to identify hematopoietic and endothelial cells were CD45, CD11b, and CD31. Antibody titration was performed with LSR Fortessa (BD Biosciences, USA). Multiple antibody concentrations were tested: 0.5, 1, 1.5, 2, 3 µg per 106 cells for the individual positive and negative markers; and 0.1, 0.2, 0.3, 0.4, 0.5 µg per 106 cells for the negative markers in combination. Proper antibody concentration was chosen using the stain index (FI: fluorescent intensity): MuSCs were isolated with FACSAria II (BD Biosciences, USA) cell sorter employing three different protocols. Protocol 1: Lin− / CD106+; Protocol 2: Lin− / CD56+ / CD29+; and Protocol 3: Lin− / CD106+ / CD29+ (Lin−: CD45− / CD11b− / CD31−). We performed 3 separate isolations for each muscle analyzed.

Cell culture

Cells were plated (2500 cells/well) in laminin coated 96-well plates in growth media (40% DMEM (Dulbecco’s modified Eagle’s medium), 40% Ham’s F-10, 20% fetal bovine serum, 1% Pen/Strep (penicillin/streptomycin), 25 ng/mL basic fibroblast growth factor.) Cells were fixed 2, 12, 72, and 120 h after isolation to determine expression of myogenic markers. Myogenic differentiation was induced on 10000 cells 12 h after isolation, employing differentiation media (DMEM, 2% horse serum, 1% Pen/Strep) as previously described (Boscolo Sesillo et al., 2019), and assessed 72 h later.

Immunostaining

Frozen tissue sections were fixed with 4% paraformaldehyde (PFA), washed in PBS (phosphate-buffered saline), and incubated for 1 h with blocking buffer (20% goat serum + 0.3% Triton X-100 in PBS) before overnight incubation with laminin primary antibody (1:200) in blocking buffer. After 3 PBS washes, the slides were incubated for 2 h with secondary antibody (Alexa Fluor 546 goat anti-rabbit IgG) in blocking buffer. After another PBS wash, the slides were post-fixed with 4% PFA, washed again and immersed in boiling antigen unmasking solution for 15 min. Slides were then washed in PBS and incubated with blocking buffer (1 h), followed by Pax7 antibody (1:100) overnight. After 3 PBS washes, the slides were incubated for 2 h with secondary antibody (Alexa Fluor 488 goat anti-mouse IgG) in blocking buffer. Cultured cells were fixed with 4% PFA, washed in PBS, and incubated with blocking buffer (1 h), followed by Pax7 (1:100), MyoD (1:100), Myogenin (1:100), or MyHC (1:100) overnight. Secondary antibodies (Alexa 546 goat anti-mouse IgG and Alexa 488 goat anti-mouse IgG) were incubated at 1:250 dilutions in blocking buffer. Nuclei were identified with DAPI (1:1000).

RNA isolation and analysis

RNA isolation was performed on freshly isolated cells with miRNeasy Micro kit per manufacturer protocol. QIAxpert was employed for RNA quantification. cDNA was obtained with SuperScript VILO cDNA Synthesis kit, and SYBR green PCR master Mix was used for qRT-PCR.

Imaging

Imaging was carried out using the Keyence BZX710 microscope (Keyence, Japan). Quantification was performed on 5–8 unmodified images per well (10X magnification) with Adobe Photoshop CS4 and ImageJ.

Statistical analysis

Data were compared between groups using one- or two-way ANOVA, followed by pairwise comparisons with Tukey’s range test when appropriate, with significance set to 5%. All statistical analyses were performed with Prism 8. Key resources table containing vendor and catalog number for all commercial products used in this study is provided.

KEY RESOURCES TABLE

Reagent or resourceSourceIdentifier
Antibodies
PE/Cy7 anti-mouse/rat CD29 antibodyBiolegend, USACat#102221, RRID:AB_528789
Mouse NCAM-1/CD56 PE-conjugated antibodyR&D Systems, USACat# FAB7820P
PE anti-rat CD106 antibodyBiolegend, USACat#200403, RRID:AB_2214210
Alexa Fluor® 647 mouse anti-rat CD45BD Biosciences, USACat#565465, RRID:AB_2739250
APC mouse anti-rat CD11bBD Biosciences, USACat#562102, RRID:AB_10896148
CD31/PECAM-1 antibody (TLD) [Alexa Fluor® 647]Novus, USACat# NB100– 64796AF647
Anti-Laminin antibody produced in rabbitSigma-Aldrich, USACat# L9393, RRID:AB_477163
Pax7DSHB, USACat# Pax7-c
Purified mouse anti-MyoDBD Biosciences, USACat#554130, RRID:AB_395255
Purified mouse anti-MyogeninBD Biosciences, USACat#556358, RRID:AB_396383
MyHCDSHB, USACat# Mf20-c
Goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 546Thermo Fisher Scientific, USACat# A11035, RRID:AB_2534093
Goat anti-mouse IgG1 Cross-adsorbed secondary antibody, Alexa Fluor 488Thermo Fisher Scientific, USACat# A21121, RRID:AB_2535764
DAPI solution (1mg/mL)Thermo Fisher Scientific, USACat#62248
Chemicals, Peptides, and Recombinant Proteins
Ham’s F-10 Nutrient MixLife Technologies, USACat#11550043
Horse SerumSigma-Aldrich, USACat#H1270–550ML
Collagenase, type II, powderLife technologies, Gibco®, USACat#17101015
Dispase II, powderLife technologies, Gibco®, USACat#17105041
LamininRoche®, SwitzerlandCat#11243217001
DMEM, low glucose, PyruvateLife technologies, Gibco®, USACat#11885092
Fetal bovine serum, qualified, heat inactivated, United StatesLife technologies, Gibco®, USACat#16140071
Penicillin-Streptomycin (10000 U/mL)Life technologies, USACat#15140163
Pepro Tech Inc human FGF-basic (154 a.a), Recombinant protein, 100ugFisher Scientific, USACat#50398738
PBS, Ph 7.4Fisher Scientific, USACat#10010023
Paraformaldehyde, 90%, Acros Organics™Fisher Scientific, USACat#169650025
Donor goat serumGemini Bio-Products, USACat#100–109
Triton X-100Sigma-Aldrich, USACat# X100–500ML
Antigen unmasking solution, citric acid basedVector Laboratories, USACat# H3300, RRID:AB_2336226
Critical Commercial Assays
miRNeasy Micro kitQiagen, USACat#217084
QIAxpert Slide-40Qiagen, USACat#990700
SuperScript VILO cDNA Synthesis kitInvitrogen, USACat#11754050
SYBR green PCR master MixLife Technologies, USACat#4367659
Experimental Models: Organisms/Strains
Rat: Sprague Dawley outbred ratEnvigo, USARGD Cat# 737903, RRID:RGD_737903
Software and Algorithms
Adobe Photoshop CS4Adobe, USANA
ImageJImageJ, USANA
Prism 7 and Prism 8GraphPad Software, Inc., USANA

Results

We first assessed in situ localization of MuSCs in the rat tibialis anterior (TA). Visual assessment of ~300 MuSCs indicated that all Pax7+ cells localized under the basal lamina with none present in the interstitial space, similar to mouse MuSCs (Fig. 1) (Yin et al., 2013). Quantification of MuSCs in rat TA revealed an average of 10 Pax7+ cells per mm2. Our results are comparable to mouse, where the density of MuSCs ranges from 5 to 20 cells/mm2 (Fig. 1) (Parisi et al., 2015; Eliazer et al., 2019; Schaaf et al., 2018).
Fig. 1.

MuSCs localization. MuSCs identified by Pax7 expression in the rat Tibialis Anterior (TA) muscle. Left: low magnification image of TA (scale bar 50 µm). Center: Zoomed in images of Pax7+ cell (scale bar 25 µm). Right: quantification of Pax7+ cells.

Determination of reliable positive markers for rat MuSC isolation

To isolate a highly enriched MuSC population, we identified commercially available antibodies suitable in rat and tested them on pooled preparations of TA, GAS, and quadriceps to determine antibody binding specificity and optimal concentrations (Figure S1). First, CD106, CD56, and CD29 antibodies were titrated through flow cytometry to confirm the expression of each marker in the muscles. Analyses were performed on the LSR Fortessa where non-treated controls were compared to cells treated with one of the five progressively increasing antibody concentrations (0.5, 1, 1.5, 2, and 3 µg per 106 cells) (Figs. S1A–S1C). Based on the stain index, the optimal concentration for all antibodies was 1.5 µg per 106 cells. Similarly, we titrated antibodies for the negative selection markers: CD31, CD45, and CD11b. Each antibody was tested separately (Figs. S1D–S1F) to assess binding specificity, and in combination to ensure that simultaneous use of multiple antibodies did not cause signal saturation (Fig. S1G). Optimal staining was achieved with 0.3 µg per 106 cells for each antibody. Guided by protocols from other models, we tested three isolation strategies in the rat TA. Protocol 1 relied on CD106 as the only positive marker. In Protocols 2 and 3, cells were concurrently stained for CD56 and CD29 or CD106 and CD29, respectively (Fig. 2A). We used single color and fluorescence minus one (FMO) controls to determine the gating system (Figure S1K–M). Using forward and side scatter parameters independent of fluorescent signal, we first excluded cellular debris and cell clusters (Fig. 2B–D, three top plots). For Protocol 1, we used DAPI negative staining to identify live cells. Within the live cell population, we then determined which lineage negative cells (CD31−/CD45−/CD11b−, Lin−) expressed CD106 (Fig. 2B). Employing Protocol 1, we identified a single putative MuSC population (P1). For Protocols 2 and 3, we utilized the lack of negative selection markers and DAPI expression to identify live Lin− cells, coupled with the expression of both positive markers to discern the presumed MuSC populations. Interestingly, expression of the CD56 marker (Protocol 2) was detectable in samples prepared from pooled hind limb muscle homogenate, but not in samples derived from TA alone, suggesting that CD56 is not conserved among different muscles. We, therefore, excluded CD56 from further experiments. In Protocol 2, we observed a clear separation of two cell populations based on CD29 expression (Fig. 2C). Using Protocol 3, we also identified two cells populations: one positive for both CD29 and CD106 and the other positive only for CD29 (Fig. 2D). We went on to further examine the following subpopulations: CD29High (P2) and CD29Low (P2b) identified using Protocol 2, and CD106+/CD29+ (P3) and CD106−/CD29+ (P3b) identified using Protocol 3 (Fig. 2C and D).
Fig. 2.

Gating approach for cell isolation protocols. (A) Experimental design for panels B–D. (TA: Tibialis Anterior). FACS plots for the gating approach used in protocols 1 (B), 2 (C), and 3 (D).

CD106 is a valid marker for isolation of rat MuSCs from tibialis anterior muscle

To test cell identity and myogenic commitment of the 5 cell populations (P1, P2, P2b, P3, and P3b) described above, we isolated cells from TA using BD Biosciences FACSAria II cell sorter. First, we compared the percentage of putative MuSCs sorted using our three different protocols (Fig. S2A). Protocols 1 and 3 yielded 1.6% for P1 (CD106+) and P3 (CD106+/CD29+) populations, which was significantly lower than 6.5% putative MuSCs isolated employing Protocol 2 (CD29High) (Figure S2A). P2b (CD29Low) constituted 9.3% and P3b (CD106−/CD29+) 12.4% of the original sorted population (Fig. S2A). After isolation, cells were plated and fixed either 2 or 12 h later to assess cell identity or cultured in growth conditions for 3 and 5 days to determine their myogenic potential (Fig. 3A). Expression of Pax7 in freshly isolated P1, P2, and P3 populations was ~90% and 80% 2 and 12 h after isolation, respectively (Fig. 3B). In contrast, only 20% of P2b (CD29Low) and 50% of P3b (CD106−/CD29+) populations expressed Pax7 2 h after isolation (Figure S2B). These results suggest that P1, P2, and P3 populations represent a highly enriched MuSCs population, whereas, only up to a half of the P2b and P3b cells were potential MuSCs. Thus, using CD29Low or CD106−/CD29+ precludes efficient isolation of a highly enriched population.
Fig. 3.

Phenotypic validation of cell populations isolated using three protocols. (A) Experimental design for panels B-D (TA: Tibialis Anterior; IF: immunofluorescence; GM: Growth Media). (B) Left: Pax7 expression in freshly isolated cells (scale bar 50 µm); right: quantification of Pax7+ cells plated for 2 and 12 h after isolation. (C) Left: MyoD expression in cultured cells (scale bar 50 µm); right: quantification of MyoD+ cells in culture for 72 h. (D) Left: myogenin expression in cultured cells (scale bar 100 µm); right: quantification of Myogenin+ cells in culture for 120 h. (E) Experimental design for panel F. (DM: Differentiation Media). (F) Left: myosin heavy chain (MyHC) expression in differentiated cells (scale bar 50 µm); right: quantification of MyHC + nuclei after 72 h in DM. (G) Quantitative real time PCR in freshly isolated cells for myogenic genes (Pax7, MyoD, Myogenin), comparing P1, P2, and P3 populations. All data are normalized to P1 population.

To assess the ability of the isolated cells to progress through myogenic lineage, cells cultured in growth media for 3 and 5 days were assessed for the expression of MyoD and myogenin, respectively. Around 80% of P1, P2, and P3 populations expressed MyoD, whereas less than 40% of the P2b and P3b cells expressed MyoD (Fig. 3C and S2C). Moreover, 20% of P1, P2, and P3 cells expressed myogenin, while myogenin was detected in less than 1% of P2b and P3b populations (Fig. 3D and S2D). Taken together, these data show that only CD106+ (P1), CD29High (P2), and CD106+/CD29+ (P3) cells express high levels of Pax7 and are capable of efficiently progressing through the myogenic lineage in vitro. To determine the ability of P1, P2, and P3 populations to complete myogenic differentiation, we placed cells in serum-deprived media for 3 days. Myosin heavy chain (MyHC), a marker of terminal differentiation, was used to calculate the differentiation index ((nuclei of MyHC+ cells/total nuclei number)*100) (Fig. 3E). P1 and P3 differentiation index was over 60%, compared to only 40% in the P2 population (Fig. 3F). Moreover, P2 cells demonstrated a lower ability to fuse, evidenced by sparse appearance of the myotubes relative to the P1 and P3 populations. (Fig. S2F). Consistent with their low ability to undergo myogenic commitment, the differentiation index of P2b and P3b cells was less than 2% (Fig. S2E). These results indicate that Protocols 1 and 3 accurately identify rat MuSCs capable of myogenic commitment and terminal differentiation. Despite high expression of Pax7, P2 (CD29High) cells were not capable of efficient differentiation or fusion compared to P1 and P3 populations. To investigate potential mechanisms underlying these differences, we analyzed myogenic gene expression by qRT-PCR on cells freshly isolated using all three protocols (Fig. 3G). A significant increase in myogenin expression was observed in the P2 population relative to P1 and P3 populations. Moreover, a trend towards reduced Pax7 gene expression was noted in P2 compared to P1 and P3 cells. These results suggest that P2 cells are more committed than P1 and P3 populations. Given that Protocol 2 led to the isolation of less undifferentiated cells that could not undergo efficient myogenic differentiation (Fig. 3F and G), this protocol was excluded from further analyses. While Protocol 1 relies solely on CD106 as a positive isolation marker, Protocol 3 depends on two positive markers: CD106 and CD29. Importantly, cells obtained from both protocols did not differ phenotypically, indicating that both protocols yield comparable MuSC populations. Given fiscal and technical advantages of employing a single positive marker for the identification of MuSCs, we focused on validating Protocol 1 in five additional rat muscles.

MuSCs can be efficiently isolated from a broad range of rat skeletal muscles employing CD106 as a single positive marker

To validate our selected protocol, we tested its reliability and efficiency in isolating MuSCs from other rat skeletal muscles, specifically GAS, DIA, and the individual pelvic floor muscles (C, ICa, and PCa). To enhance population separation during isolation, which increases MuSC yield, we first optimized the gating for Protocol 1 (Fig. 4A). Based on MuSC size, determined during the initial experiments (Fig. 2B), we applied a gate to select for live small cells. Further gates were progressively designed to define single cell populations, Lin− cells, and CD106+ cells. This new gating system was reproducible among all muscles evaluated, leading to a consistent isolation of 2–3% of MuSC from the initial number of cells and improving upon 1.6% yield from the previous gating system (Fig. 4B, Figure S2A and Figure S3A). Upon isolation, cells were plated in growth media for 2 h, fixed, and assessed for Pax7 expression to evaluate their identity (Fig. 4C). Consistent with the results obtained for TA, ~90% of cells isolated from all other muscles expressed Pax7 (Fig. 4D). Moreover, high expression of MyoD and myogenin was present when the cells were placed in culture for 3 and 5 days, respectively (Figs. S3B–S3E). Cells placed in serum-deprived media for 3 days exhibited a differentiation index between 70 and 80% (Fig. 4E and F). These results confirm that Protocol 1 can be reliably employed in different muscles in the rat model for isolation of a highly enriched MuSC population capable of myogenic commitment and terminal differentiation.
Fig. 4.

Phenotypic validation of cells isolated using Protocol 1 in gastrocnemius, diaphragm, and pelvic floor muscles. (A) FACS plots for the optimized gating for protocol 1. (GAS: Gastrocnemius; DIA: Diaphragm; C: coccygeus; ICa: iliocaudalis; PCa: pubocaudalis; GM: Growth Media; IF: immunofluorescence). (B) FACS plots showing MuSCs (black gate) in GAS, DIA, C, ICa, and PCa. (C) Experimental design for panel D. (D) Left: Pax7 expression in freshly isolated cells (scale bar 50 µm); right: quantification of Pax7+ cells plated for 2 h after isolation. (E) Experimental design for panel F. (DM: Differentiation Media). (F) Left: MyHC expression in differentiated cells (scale bar 50 µm); right: quantification of MyHC + nuclei after 72 h in DM.

Discussion

The positive markers selected for our studies were based on the existing literature and antibody availability for rat, and included vascular cell adhesion molecule (VCAM-1, CD106), neural cell adhesion molecule (NCAM, CD56), and β1-integrin (CD29). CD106 is a trans-membrane protein in the immunoglobulin superfamily that has been successfully used for isolation of mouse MuSCs (Liu et al., 2015). Importantly, expression of this protein in quiescent cells is required for maintenance of their basal function and prevention of premature lineage progression (Choo et al., 2017). The current study demonstrates, for the first time, that CD106 is a reliable marker for the isolation of a highly enriched MuSC population from various rat skeletal muscles. Indeed, CD106+/CD45−/CD31−/CD11b− cells express Pax7 at high levels and are capable of myogenic commitment and full differentiation into myotubes. CD56 has been mainly described as a marker of quiescent human MuSCs (Alexander et al., 2016; Uezumi et al., 2016). In rodents, expression of this marker has been associated only with MuSCs activated in response to either differentiation stimuli in vitro or denervation in vivo (Capkovic et al., 2008; Covault and Sanes, 1985). While we observed CD56 expression when analyzing whole muscle cell preparations (Fig. S1C), expression was not found in Lin− gated cells during the sorting process. CD56 is likely expressed in the neuromuscular junctions and not in the MuSCs that we want to isolate (Covault and Sanes, 1985). CD29, has been previously used for the isolation of MuSCs from mouse, pig, and cow (Ding et al., 2017, 2018; Maesner et al., 2016). It is a member of the integrin family and interacts with collagen, fibronectin, and laminin depending on its heterodimer binding partner (Hynes, 2002). It is highly expressed in MuSCs and is necessary for maintenance of quiescence in homeostatic conditions and cell proliferation after injury (Rozo et al., 2016). Moreover, in myoblasts, CD29 is indispensable for cell fusion (Schwander et al., 2003). In contrast to the previous studies, we found that CD29High cells have reduced Pax7 and increased myogenin gene expression (Fig. 3G), and fuse less. The antibody used for the isolation of cells in Protocol 2 is specific for α4β1 integrin immunogen, preferentially selecting for cells expressing the α4 subunit in association with CD29. The resultant cell population is therefore enriched for α4β1 integrin, while being depleted off α5-α7β1 integrins. Previous work suggests that the interplay between integrin heterodimers is essential for proper myogenic differentiation and fusion (Yang et al., 1996). We believe that the lack of integrin heterodimer heterogeneity in P2 cells accounts for the phenotype observed in our experiments. Currently, the majority of MuSC studies are performed in a mouse, owing to the opportunities for genetic manipulation of this model (Huang et al., 2011). However, the small size of these animals significantly limits the amount of muscle tissue, which in turn restricts the number of MuSCs that can be isolated making it hard to perform experiments demanding large cell numbers, such as RNA or ChIP sequencing. The insufficient yield of MuSCs from small mouse muscles necessitates pooling of different muscles from the same animal or pooling of the same muscle type from multiple animals (van Velthoven et al., 2017; Sampath et al., 2018). Pooling different specimens masks the intrinsic variability of different muscles or individual organisms, potentially affecting results and their interpretation. Moreover, given recent evidence that MuSCs are highly heterogeneous, maintaining muscle and animal identity in future studies could enhance our understanding of diverse MuSC populations (Cornelison and Wold, 1997; Kuang et al., 2007). Using the rat model (10 times larger than a mouse) can help scientists circumvent these limitations and expand the existing studies to smaller muscles previously set aside due to technical constraints. For instance, the regenerative potential of MuSCs from extensor digitorum longus and soleus, small muscles that differ with respect to MuSC number and fiber phenotype, have never been directly compared (Yin et al., 2013, Soukup et al., 2002). Using our optimized protocol, we obtain a proportion of the sorted cells similar to the mouse (Fig. 4A and S3A) (Liu et al., 2015). Our in situ evaluations (Fig. 1) showed an average of 10 Pax7+ cells per mm2, which is also comparable to the number of MuSCs per mm2 in mouse (Parisi et al., 2015; Eliazer et al., 2019; Schaaf et al., 2018). Given the above and the larger size of the rat muscles, one can isolate a greater number of MuSCs from the rat. This opens new avenues for investigations focused on the autonomous function of MuSCs derived from small-sized muscles. Larger animal models, such as non-human primates, pig, or cow, would, of course, allow isolation of an even greater number of MuSCs. However, these models are costly relative to the rat, and numerous constraints related to housing and handling of these species exist.

Conclusions

In conclusion, a single positive selection marker can be used to reliably isolate MuSCs from a variety of rat skeletal muscles. The use of the rat model for the study of MuSCs offers a major advantage to the skeletal muscle research field, enabling investigations of single muscles of different sizes and individual animals.
  40 in total

1.  An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration.

Authors:  Christoph Lepper; Terence A Partridge; Chen-Ming Fan
Journal:  Development       Date:  2011-09       Impact factor: 6.868

2.  Sprague Dawley Rag2-Null Rats Created from Engineered Spermatogonial Stem Cells Are Immunodeficient and Permissive to Human Xenografts.

Authors:  Fallon K Noto; Valeriya Adjan-Steffey; Goutham Narla; Tseten Y Jamling; Min Tong; Kameswaran Ravichandran; Wei Zhang; Angela Arey; Christopher B McClain; Eric Ostertag; Sahar Mazhar; Jaya Sangodkar; Analisa DiFeo; Jack Crawford
Journal:  Mol Cancer Ther       Date:  2018-09-11       Impact factor: 6.261

Review 3.  Satellite cells and the muscle stem cell niche.

Authors:  Hang Yin; Feodor Price; Michael A Rudnicki
Journal:  Physiol Rev       Date:  2013-01       Impact factor: 37.312

4.  CD82 Is a Marker for Prospective Isolation of Human Muscle Satellite Cells and Is Linked to Muscular Dystrophies.

Authors:  Matthew S Alexander; Anete Rozkalne; Alessandro Colletta; Janelle M Spinazzola; Samuel Johnson; Fedik Rahimov; Hui Meng; Michael W Lawlor; Elicia Estrella; Louis M Kunkel; Emanuela Gussoni
Journal:  Cell Stem Cell       Date:  2016-09-15       Impact factor: 24.633

5.  Beyond knockout rats: new insights into finer genome manipulation in rats.

Authors:  Guanyi Huang; Chang Tong; Dhruv S Kumbhani; Charles Ashton; Hexin Yan; Qi-Long Ying
Journal:  Cell Cycle       Date:  2011-04-01       Impact factor: 4.534

6.  Fibre type composition of soleus and extensor digitorum longus muscles in normal female inbred Lewis rats.

Authors:  Tomás Soukup; Gisela Zacharová; Vika Smerdu
Journal:  Acta Histochem       Date:  2002       Impact factor: 2.479

7.  Comparison of pelvic muscle architecture between humans and commonly used laboratory species.

Authors:  Marianna Alperin; Lori J Tuttle; Blair R Conner; Danielle M Dixon; Margie A Mathewson; Samuel R Ward; Richard L Lieber
Journal:  Int Urogynecol J       Date:  2014-06-11       Impact factor: 2.894

8.  Satellite cell of skeletal muscle fibers.

Authors:  A MAURO
Journal:  J Biophys Biochem Cytol       Date:  1961-02

9.  Established cell surface markers efficiently isolate highly overlapping populations of skeletal muscle satellite cells by fluorescence-activated cell sorting.

Authors:  Albert E Almada; Amy J Wagers; Claire C Maesner
Journal:  Skelet Muscle       Date:  2016-11-08       Impact factor: 4.912

10.  Induction of muscle stem cell quiescence by the secreted niche factor Oncostatin M.

Authors:  Srinath C Sampath; Srihari C Sampath; Andrew T V Ho; Stéphane Y Corbel; Joshua D Millstone; John Lamb; John Walker; Bernd Kinzel; Christian Schmedt; Helen M Blau
Journal:  Nat Commun       Date:  2018-04-18       Impact factor: 14.919

View more
  3 in total

Review 1.  In Vitro Culturing of Adult Stem Cells: The Importance of Serum and Atmospheric Oxygen.

Authors:  Maša Čater; Gregor Majdič
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Quantifying the Effects of Aging on Morphological and Cellular Properties of Human Female Pelvic Floor Muscles.

Authors:  Mary Rieger; Pamela Duran; Mark Cook; Simon Schenk; Manali Shah; Marni Jacobs; Karen Christman; Deborah M Kado; Marianna Alperin
Journal:  Ann Biomed Eng       Date:  2021-03-08       Impact factor: 3.934

3.  The Expression Profiles of mRNAs and lncRNAs in Buffalo Muscle Stem Cells Driving Myogenic Differentiation.

Authors:  Ruimen Zhang; Jinling Wang; Zhengzhong Xiao; Chaoxia Zou; Qiang An; Hui Li; Xiaoqing Zhou; Zhuyue Wu; Deshun Shi; Yanfei Deng; Sufang Yang; Yingming Wei
Journal:  Front Genet       Date:  2021-07-07       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.